Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer

Trial Profile

Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Rocapuldencel-T (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 19 Apr 2017 Planned primary completion date changed from 14 Apr 2017 to 14 Jul 2017.
    • 11 Feb 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
    • 15 Oct 2014 Status changed from 'not yet recruiting' to 'recruiting' as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top